Skip to content
naulon
Get started

Not checked for notices yet.

Insights into the tumor microenvironment of B cell lymphoma

Wern Lynn Ng, Stephen M. Ansell, Patrizia Mondello

Journal of Experimental & Clinical Cancer Research · 2022

doi:10.1186/s13046-022-02579-9

References 204

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.
    Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis · 2015
    No notice
  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.
    LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model · 2015
    No notice
  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  75. 75.
    Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity · 2015
    No notice
  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  89. 89.
    ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation · 2016
    No notice
  90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  94. 94.
    Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer · 2015
    No notice
  95. 95.
    PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma · 2016
    No notice
  96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  100. 100.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  101. 101.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  102. 102.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  103. 103.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  104. 104.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  105. 105.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  106. 106.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  107. 107.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  108. 108.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  109. 109.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  110. 110.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  111. 111.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  112. 112.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  113. 113.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  114. 114.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  115. 115.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  116. 116.
    Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma · 2017
    No notice
  117. 117.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  118. 118.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  119. 119.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  120. 120.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  121. 121.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  122. 122.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  123. 123.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  124. 124.
    Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis · 2017
    No notice
  125. 125.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  126. 126.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  127. 127.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  128. 128.
    Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations · 2018
    No notice
  129. 129.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  130. 130.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  131. 131.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  132. 132.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  133. 133.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  134. 134.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  135. 135.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  136. 136.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  137. 137.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  138. 138.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  139. 139.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  140. 140.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  141. 141.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  142. 142.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  143. 143.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  144. 144.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  145. 145.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  146. 146.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  147. 147.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  148. 148.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  149. 149.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  150. 150.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  151. 151.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  152. 152.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  153. 153.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  154. 154.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  155. 155.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  156. 156.
    Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications · 2019
    No notice
  157. 157.
    Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment · 2019
    No notice
  158. 158.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  159. 159.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  160. 160.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  161. 161.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  162. 162.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  163. 163.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  164. 164.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  165. 165.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  166. 166.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  167. 167.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  168. 168.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  169. 169.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  170. 170.
    Role of CD47 in Hematological Malignancies · 2020
    No notice
  171. 171.
    Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment · 2020
    No notice
  172. 172.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  173. 173.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  174. 174.
    Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade · 2020
    No notice
  175. 175.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  176. 176.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  177. 177.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  178. 178.
    CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis · 2021
    No notice
  179. 179.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  180. 180.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  181. 181.
    CTLA-4 in Regulatory T Cells for Cancer Immunotherapy · 2021
    No notice
  182. 182.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  183. 183.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  184. 184.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  185. 185.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  186. 186.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  187. 187.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  188. 188.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  189. 189.
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89 Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody · 2021
    No notice
  190. 190.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  191. 191.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  192. 192.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  193. 193.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  194. 194.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  195. 195.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  196. 196.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  197. 197.
    The genomic and transcriptional landscape of primary central nervous system lymphoma · 2022
    No notice
  198. 198.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  199. 199.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  200. 200.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  201. 201.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  202. 202.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  203. 203.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  204. 204.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.